Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 21, 2023
Reporting Period: The filing reports on events consummated on March 21, 2023, regarding a private placement initiated on March 13, 2023.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The primary financial data point disclosed is:
- Debt Financing: The Company consummated the sale of a Senior Secured Convertible Note with an initial principal amount of up to $11,111,110.
- Liquidity: Proceeds from the Note sale are intended to provide liquidity, though specific cash balance figures are not provided in this text.
Material Changes
The filing details the following material changes compared to the prior period:
- Debt Obligation: Creation of a direct financial obligation via the issuance of the Senior Secured Convertible Note.
- Equity Structure: Potential future dilution due to the convertible nature of the Note, with shares issuable upon conversion.
- Corporate Governance: Execution of a Voting Agreement with parent company PAVmed Inc., which holds approximately 72% of the Company's common stock. PAVmed agreed to vote its shares in favor of specific Stockholder Resolutions.
- Registration Rights: Execution of a Registration Rights Agreement granting the Investor rights regarding the resale of underlying common stock.
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing focuses on the execution of the financing transaction rather than providing forward-looking operational guidance or revenue projections.
Risks and Contingencies:
- Securities Exemption: The Convertible Notes and underlying shares were sold pursuant to Section 4(a)(2) of the Securities Act of 1933, exempting them from registration requirements as they did not involve a public offering.
- Contractual Limitations: The filing notes that representations and warranties in the attached agreements are made solely for the benefit of the parties and for risk allocation, not as general factual statements about the Company.
Investor Verification Checklist
- Verify the specific terms of the Senior Secured Convertible Note (interest rate, conversion price, maturity date) in the Securities Purchase Agreement referenced in the Prior Form 8-K (filed March 14, 2023).
- Confirm the identity of the accredited Investor and the use of proceeds from the $11,111,110 financing.
- Review the Voting Agreement to understand the specific "Stockholder Resolutions" that PAVmed Inc. has committed to support.
- Assess the impact of the 72% ownership stake held by PAVmed Inc. on future corporate control and decision-making.